Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection
Lorenza Romani, Francesca Ippolita Calò Carducci, Sara Chiurchiù, Laura Cursi, Maia De Luca, Martina Di Giuseppe, Andrzej Krzysztofiak, Laura Lancella, Paolo Palma, Leonardo Vallesi, Tiziana Corsetti, Andrea Campana, Emanuele Nicastri, Paolo Rossi, Stefania Bernardi
Abstract
Monoclonal antibody therapies for COVID-19 have been frequently used in adults, whereas there are little data regarding the safety or efficacy of monoclonal antibody treatments in pediatric patients affected by COVID-19. We report our experience in the administration of mAb as a treatment for SARS-CoV-2 infection in children aged from 24 days to 18 years old.
Topics & Concepts
Monoclonal antibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Medicine2019-20 coronavirus outbreakVirologyAntibodyMonoclonalImmunologyInternal medicineOutbreakInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19